Biomimetic nanoparticles directly remodel immunosuppressive microenvironment for boosting glioblastoma immunotherapy

Wang, Tingting; Zhang, Hao; Qiu, Weibao; Han, Yaobao; Liu, Hanghang; Li, Zhen

doi:10.1016/j.bioactmat.2021.12.029

Cited by 54 publications

(64 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At the same time, the strategy relied on co-stimulation with immune agonist, CpG, and tumor-associated antigens released by photothermal therapy in situ, promising to elicit a practical, durable tumor-specific immune response advantageous for alleviating immunosuppression. Zhen et al constructed a biomimetic nanoparticle (CS-I/J@CM NPs) combining light, sound and immune checkpoint therapy for the treatment of glioblastoma ( Figure 7 ) [ 63 ]. The encapsulation of TCMVs can improve the targeting ability and enrichment of particles at tumor sites.…”

Section: The Application Of Tumor Cell-derived Membrane Vesicles To P...mentioning

confidence: 99%

See 1 more Smart Citation

Tumor-Derived Membrane Vesicles: A Promising Tool for Personalized Immunotherapy

Cao

Wang

et al. 2022

Pharmaceuticals

View full text Add to dashboard Cite

Tumor-derived membrane vesicles (TDMVs) are non-invasive, chemotactic, easily obtained characteristics and contain various tumor-borne substances, such as nucleic acid and proteins. The unique properties of tumor cells and membranes make them widely used in drug loading, membrane fusion and vaccines. In particular, personalized vectors prepared using the editable properties of cells can help in the design of personalized vaccines. This review focuses on recent research on TDMV technology and its application in personalized immunotherapy. We elucidate the strengths and challenges of TDMVs to promote their application from theory to clinical practice.

show abstract

Section: The Application Of Tumor Cell-derived Membrane Vesicles To P...mentioning

confidence: 99%

“… Integrated CS-I/J@CM NPs remodel the tumor immunosuppressive microenvironment to improve glioblastoma immunotherapy [ 63 ]. …”

Section: Figurementioning

confidence: 99%

Tumor-Derived Membrane Vesicles: A Promising Tool for Personalized Immunotherapy

Cao

Wang

et al. 2022

Pharmaceuticals

View full text Add to dashboard Cite

show abstract

“…This was followed by covering the NP surface with tumor cell membrane to improve the targetability towards cancer tissues. The fabricated nanoformulation could reprogram the tumor immunosuppressive microenvironment and activate the immune response via increasing the number of M1-phenotype macrophages (by increasing ROS levels by near infrared II (NIR II) irradiation) and anti-tumor CD8 + T cells at the tumor site along with reducing PD-L1 expression and Treg cells infiltration [ 207 ].…”

Section: Gbm–immunotherapy–bioengineeringmentioning

confidence: 99%

Immunology Meets Bioengineering: Improving the Effectiveness of Glioblastoma Immunotherapy

Fekrirad

Behrooz

Ghaemi

et al. 2022

Cancers

View full text Add to dashboard Cite

Glioblastoma (GBM) therapy has seen little change over the past two decades. Surgical excision followed by radiation and chemotherapy is the current gold standard treatment. Immunotherapy techniques have recently transformed many cancer treatments, and GBM is now at the forefront of immunotherapy research. GBM immunotherapy prospects are reviewed here, with an emphasis on immune checkpoint inhibitors and oncolytic viruses. Various forms of nanomaterials to enhance immunotherapy effectiveness are also discussed. For GBM treatment and immunotherapy, we outline the specific properties of nanomaterials. In addition, we provide a short overview of several 3D (bio)printing techniques and their applications in stimulating the GBM microenvironment. Lastly, the susceptibility of GBM cancer cells to the various immunotherapy methods will be addressed.

show abstract

“…Electron microscopy showed that claudin‐5, occludin, and ZO‐1 decreased after sonication in rats, and gradually returned to presonication levels (Liu, Gong, et al, 2020). Ultrasound‐mediated BBB opening has been applied to deliver conventional chemotherapeutic drugs and nanoparticles for the treatment of malignant gliomas and metastatic brain tumors (Liu, Ren, et al, 2019; Liu, Wu, et al, 2019; Ren et al, 2020; Wang, Zhang, et al, 2022; Xu et al, 2022; Yuan et al, 2022; Zhang et al, 2018).…”

Section: Bbb Alteration In Brain Diseases and Targeting Delivery Stra...mentioning

confidence: 99%

Brain‐targeting drug delivery systems

Liu

Jiang

2022

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Brain diseases, including neurodegenerative diseases, acute ischemic stroke and brain tumors, have become a major health problem and a huge burden on society with high morbidity and mortality. However, most of the current therapeutic drugs can only relieve the symptoms of brain diseases, and it is difficult to achieve satisfactory therapeutic effects fundamentally. Extensive studies have shown that the therapeutic effects of brain diseases are mainly affected by two factors: the conservation of the blood–brain barrier (BBB) and the complexity of the brain micro‐environment. Brain‐targeting drug delivery systems provide new possibilities for overcoming these barriers with versatility. In this review, it provides an overview of BBB alteration and discusses targeting delivery strategies for brain diseases therapy. Furthermore, delivery systems which are designed to modulate the brain micro‐environment with synergistic effects were also highlighted. This article is categorized under: Therapeutic Approaches and Drug Discovery > Emerging Technologies

show abstract

Biomimetic nanoparticles directly remodel immunosuppressive microenvironment for boosting glioblastoma immunotherapy

Cited by 54 publications

References 56 publications

Tumor-Derived Membrane Vesicles: A Promising Tool for Personalized Immunotherapy

Tumor-Derived Membrane Vesicles: A Promising Tool for Personalized Immunotherapy

Immunology Meets Bioengineering: Improving the Effectiveness of Glioblastoma Immunotherapy

Brain‐targeting drug delivery systems

Contact Info

Product

Resources

About